Philip Niles, MD, MBA

Explore how extended anti‑VEGF dosing impacts cost and care burden, plus key evidence gaps and next‑gen targets for AMD, DME and RVO.

Real-world retina data shows aflibercept 8 mg and faricimab extend anti-VEGF intervals and target Ang2/Tie2 for AMD and DME.

Real-world retina data shows how aflibercept 8 mg and faricimab extend anti-VEGF intervals, guiding treat-and-extend for AMD and DME.

Real-world anti‑VEGF outcomes lag trials as durability and missed injections matter; learn how evidence guides everyday wet AMD decisions.

How anti-VEGF injections reshape wet AMD, DME, and vein occlusion care, preserving vision—plus what real-world access barriers mean for patients.

Nicholas G. Anderson, MD; Philip Niles, MD, MBA; Kevin U. Stephens, Sr., JD, MD; and Jim Kenney, RPh, MBA, provide insight on unmet needs and future directions for the treatment of wet AMD and DME.

Philip Niles, MD, MBA; Nicholas G. Anderson, MD; and Kevin U. Stephens, Sr., JD, MD, explore the role of faricimab in the current treatment landscape for wet AMD.

Nicholas G. Anderson, MD, leads a discussion on how the first ophthalmic formulation of bevacizumab may impact the wet AMD treatment paradigm.

Philip Niles, MD, MBA; Nicholas G. Anderson, MD; Kevin U. Stephens, Sr., JD, MD; and Jim Kenney, RPh, MBA, comment on safety and cost considerations for the uptake of anti-VEGF biosimilars such as ranibizumab and discuss the impact on the future treatment landscape for wet AMD.

Nicholas G. Anderson, MD, explores the use of a novel port delivery system with ranibizumab for the treatment of wet AMD.

Philip Niles, MD, MBA; Jim Kenney, RPh, MBA; and Nicholas G. Anderson, MD, discuss the clinical and economic implications of a delay in therapy for wet AMD and DME.

Philip Niles, MD, MBA; Kevin U. Stephens, Sr., JD, MD; Nicholas G. Anderson, MD; and Jim Kenney, RPh, MBA, comment on managing the utilization of anti-VEGF agents for wet AMD and DME, including the impact of step edits on care.

Nicholas G. Anderson, MD, shares factors to consider when selecting an anti-VEGF agent for treatment of wet AMD and DME.

Philip Niles, MD, MBA, leads a discussion on treatment approaches that are utilized with anti-VEGF agents in wet AMD and DME, including payer considerations for approaches such as treat and extend.

Nicholas G. Anderson, MD; Philip Niles, MD, MBA; and Kevin U. Stephens, Sr., JD, MD, provide insight on the anti-VEGF treatment landscape and options for patients with wet AMD and DME.

Philip Niles, MD, MBA; Kevin U. Stephens, Sr., JD, MD; Jim Kenney, RPh, MBA; and Nicholas G. Anderson, MD, review goals of therapy for patients with wet age-related macular degeneration (AMD) and discuss a health plan perspective for the management of therapy.

Kevin U. Stephens, Sr., JD, MD, leads a discussion exploring the key drivers of cost for patients with wet age-related macular degeneration (AMD).

Nicholas G. Anderson, MD, and Philip Niles, MD, MBA, provide an overview of diabetic macular edema (DME) and the impact of vision impairment on a patient’s quality of life.

Philip Niles, MD, MBA, and Nicholas G. Anderson, MD, define wet age-related macular degeneration (AMD) and review clinical manifestations of the disease.